PharmAust Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Michael Thurn

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.8yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO

Michael Thurn

less than a year

Tenure

Dr. Michael Thurn, Ph D., is Chief Executive Officer of PharmAust Limited from September 1, 2023 and is its Director since 2023. He served as a Chief Operating Officer of Botanix Pharmaceuticals Limited si...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sam Wright	Finance Director	16.7yrs	AU$138.00k	1.27% A$ 877.9k
Fiona Milner	General Manager of Epichem Pty Ltd	1.8yrs	AU$212.10k	no data
Michael Thurn	CEO & Director	less than a year	no data	no data
Gary Pitt	Head of Chemistry	no data	no data	no data
James Rixson	Head of Production	no data	no data	no data

1.8yrs

Average Tenure

Experienced Management: ECQ's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Sam Wright	Finance Director	15.5yrs	AU$138.00k	1.27% A$ 877.9k
Michael Thurn	CEO & Director	1.3yrs	no data	no data
Roger Aston	Non-Executive Chairman	10.7yrs	AU$287.30k	3.81% A$ 2.6m
Neville Bassett	Non-Executive Director	5.5yrs	AU$40.00k	0.13% A$ 89.0k
Robert Bishop	Non-Executive Director	10.5yrs	AU$141.44k	2.41% A$ 1.7m
Thomas Duthy	Non-Executive Director	less than a year	no data	0.063% A$ 43.9k
Christian Schirvel	Veterinary Clinical Advisory Board Member	6.5yrs	no data	no data
Angela Frimberger	Veterinary Clinical Advisory Board Chair	6.5yrs	no data	no data
Barbara Kitchell	Veterinary Advisory Board Member	6.3yrs	no data	no data

6.5yrs

Average Tenure

66yo

Average Age

Experienced Board: ECQ's board of directors are considered experienced (6.5 years average tenure).

PharmAust Management

Management criteria checks 1/4

Key information

Recent management updates

PharmAust Limited, Annual General Meeting, Nov 20, 2023

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

PharmAust Limited Announces Resignation of Richard Mollard as Chief Scientific Officer

Recent updates

PharmAust Limited has completed a Follow-on Equity Offering in the amount of AUD 3.459 million.

PharmAust Limited has announced a Derivatives Offering in the amount of AUD 39.612456 million.

PharmAust Limited, Annual General Meeting, Nov 20, 2023

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

First half 2023 earnings released: EPS: AU$0 (vs AU$0.004 loss in 1H 2022)

PharmAust Limited Progresses to Elevated Doses in MND Patients

PharmAust Limited Completes First Cohort of Six Patients in Its Phase 1/2 Clinical Trial of Lead Drug Candidate Monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis

PharmAust Limited Announces MND Trial Completes Enrolment of First Patient Cohort

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

PharmAust Limited Recruits First Pet Dog with B Cell Lymphoma in US Canine Phase 2 Trial Assessing the Efficacy of Monepantel Treatment

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in FY 2021)

Pharmaust Updates on Canine Cancer Trials

PharmAust Limited Announces Resignation of Richard Mollard as Chief Scientific Officer

Pharmaust Limited Announces Arrival of Mpl Tablets in Melbourne for Motor Neuron Disease Clinical Trial

PharmAust Limited Expands Lymphoma Canine Trial to the USA

No independent directors

PharmAust Limited Announces Preliminary MPL Anti-Viral Leukaemia Preclinical WEHI Results

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

First half 2022 earnings: Revenues and EPS in line with analyst expectations

PharmAust Limited Provides Update on Manufacture of MPL & Tablets for Clinical Trials

Full year 2021 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2020)

Pharmaust Limited Achieves Phase IIB Dog Trial's Interim Clinical Endpoints

PharmAust Receives Ethics Approval for Phase I Trial of Monepantel in Motor Neurone Disease

PharmAust Limited Announces Phase IIb Canine Trial Identifies Therapeutic Window for MPL

PharmAust Ltd Provides an Update on Phase IIb Trial Testing the Effects of Monepantel Upon Pet Owners' Dogs with Treatment Naïve B Cell Lymphoma

PharmAust Limited Announces Monepantel COVID-19 Testing in the Netherlands

PharmAust and Leiden University Medical Centre Provide Update on Monepantel COVID-19 Testing

PharmAust and Olivia Newton-John Cancer Research Institute to Continue MPL Pre-clinical Investigations

PharmAust Ltd to Commence Phase IIb Dog Cancer Trial

PharmAust Limited Provides an Update on Analysis at the Olivia Newton-John Cancer Research Institute Investigating the Mechanism of Action of Monepantel Upon Cancer Cells

Pharmaust Ltd, Entered into A Service Agreement with Leiden University Medical Center (Lumc) in Netherlands for Lumc to Test

Full year earnings released - €0.0046 loss per share

Full year earnings released - €0.0046 loss per share

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age